Literature DB >> 16946455

Structured treatment interruptions--new findings.

Constance A Benson1.   

Abstract

A number of recent studies have examined structured treatment interruption (STI) of antiretroviral therapy using CD4+ cell count-guided or time-based strategies in patients with chronic HIV infection and stable suppression of HIV RNA. On balance, data from these studies indicate that STI is associated with worse immunologic, virologic, and clinical outcomes than continuous antiretroviral therapy. However, the potential may still exist for use of short-term STI to manage drug toxicities in patients in this setting or to assess immunologic and virologic outcomes of novel interventions in carefully controlled clinical trials. This article summarizes a presentation on STI made by Constance A. Benson, MD, at the International AIDS Society-USA course in San Francisco in April 2006.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16946455

Source DB:  PubMed          Journal:  Top HIV Med        ISSN: 1542-8826


  3 in total

Review 1.  Modeling HIV persistence, the latent reservoir, and viral blips.

Authors:  Libin Rong; Alan S Perelson
Journal:  J Theor Biol       Date:  2009-06-17       Impact factor: 2.691

2.  Short-term HIV-1 treatment interruption is associated with dysregulated TLR-stimuli responsiveness.

Authors:  Salma Nowroozalizadeh; Lindvi Gudmundsdotter; Bo Hejdeman; Lena Andersson; Joakim Esbjörnsson; Patrik Medstrand; Eric Sandström; Hans Gaines; Britta Wahren; Marianne Jansson
Journal:  Hum Vaccin Immunother       Date:  2013-06-04       Impact factor: 3.452

3.  Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor.

Authors:  Rachel S Leibman; Max W Richardson; Christoph T Ellebrecht; Colby R Maldini; Joshua A Glover; Anthony J Secreto; Irina Kulikovskaya; Simon F Lacey; Sarah R Akkina; Yanjie Yi; Farida Shaheen; Jianbin Wang; Keith A Dufendach; Michael C Holmes; Ronald G Collman; Aimee S Payne; James L Riley
Journal:  PLoS Pathog       Date:  2017-10-12       Impact factor: 6.823

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.